I happily buy it full-priced, but I’m stocking up while it’s on sale.

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 months to less than 24 months with mild to ...

Patients with atopic dermatitis since childhood show a greater psychosocial burden than those with the disease since adolescence; however, no variation in allergic comorbidities is observed.

The study1 by Emma Guttman-Yassky and colleagues represents an important and innovative contribution to the evolving treatment landscape of moderate-to-severe atopic dermatitis, particularly by ...

Adults with more severe atopic dermatitis are at risk for sleep and memory disturbances, according to results of a recent study.

Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 as a treatment for ...

When confronted with chronic eczematous dermatitis, clinicians should try to differentiate between intrinsic (atopic dermatitis [AD]) and extrinsic (allergic or irritant contact dermatitis) causes. AD ...

TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist ...

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

What is contact dermatitis? Contact dermatitis is a reaction that occurs when something touches your skin and triggers a rash. The rash may appear right away or it could take some time to develop.

Machine learning models can predict the risk for developing moderate-to-severe persistent asthma and allergic rhinitis in children with early-life AD.

Amlitelimab is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis.